Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-ζ activating signal

Experimental Hematology

Volumn 35, Issue 9, 2007, Pages 1388-1397

  Marin, Virna ^a   Kakuda, Harumi ^b   Dander, Erica ^a   Imai, Chihaya ^b   Campana, Dario ^b   Biondi, Andrea ^a   D'Amico, Giovanna ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD19 ANTIBODY; CD28 ANTIGEN; CELL PROTEIN; CHIMERIC PROTEIN; CYTOKINE; DAP10 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE ANTIGEN RECEPTOR; LYMPHOTOXIN; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DNA MODIFICATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; B-LYMPHOCYTES; BONE MARROW CELLS; CELLS, CULTURED; CHILD; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC;

EID: 34548129970     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.05.018     Document Type: Article

References (84)

1. Bordignon C., Carlo-Stella C., Colombo M.P., et al. Cell therapy: achievements and perspectives. Haematologica 84 (1999) 1110-1149
2. Blair A., Goulden N.J., Libri N.A., Oakhill A., and Pamphilon D.H. Immunotherapeutic strategies in acute lymphoblastic leukemia relapsing after stem cell transplantation. Blood Rev 19 (2005) 289-300
3. Stripecke R., Levine A.M., Pullarkat V., and Cardoso A.A. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex-vivo culture and gene transfer methods. Leukemia 16 (2002) 1974-1983
4. Velders M.P., ter Horst S.A., and Kast W.M. Prospect for immunotherapy of acute lymphoblastic leukemia. Leukemia 15 (2001) 701-706
5. Kolb H.J., Simoes B., and Schmid C. Cellular immunotherapy after allogeneic stem cell transplantation in hematological malignancies. Curr Opin Oncol 16 (2004) 167-173
6. Marin V., Dander E., Biagi E., et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol 34 (2006) 1218-1228
7. Schmidt-Wolf I.G.H., Negrin R.S., Kiem H., Blume K.G., and Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174 (1991) 139-149
8. + NKT cells in humans and mice. J Clin Immunol 22 (2002) 131-136
9. Introna M., Franceschetti M., Ciocca A., Borleri G., Conti E., and Golay J. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 38 (2006) 621-627
10. Verneris M.R., Ito M., Baker J., Arshi A., Negrin R.S., and Shizuru J.A. Engineering hematopoietic grafts: purified allogeneic haematopoietic stem cells plus expanded CD8+ NKT cells in the treatment of lymphoma. Biol Blood Marrow Transpl 7 (2001) 532-542
11. Dsrobyski W.R., Majewski D., Ozker K., and Hanson G. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-verus-host disease but retain their ability to facilitate alloengraftment. J Immunol 161 (1998) 2610-2619
12. Edinger M., Cao Y.A., Verneris M.R., Bachmann M.H., Contag C.H., and Negrin R.S. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101 (2003) 640-648
13. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9 (2003) 279-286
14. Cooper L.J., Al-Kadhimi Z., Serrano L.M., et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by costransfer of T cells modified to present influenza MP1. Blood 166 (2005) 1622-1631
15. Brocker T., and Karjalainen K. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. J Exp Med 181 (1995) 1653-1659
16. Brocker T. Chimeric Fv-ζ or FV-ε{lunate} receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96 (2000) 1999-2001
17. + T cells in human immunodeficiency virus-infected subjects. Blood 96 (2000) 785-793
18. Walker R.E., Bechtel C.M., Natarajan V., et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96 (2000) 467-474
19. Cardoso A.A., Schultze J.L., Boussiotis V.A., et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 88 (1996) 41-48
20. Liebowitz D.N., Lee K.P., and June C.H. Co-stimulatory approaches to adoptive immunotherapy. Curr Opin Oncol 10 (1998) 533-541
21. Tan P., Anasetti C., Hansen J.A., et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177 (1993) 165-173
22. Harding F.A., McArthur J.G., Gross J.A., Raulet D.H., and Allison J.P. CD28-mediated signalling costimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 6370 (1992) 607-609
23. Imai C., Mihara K., Andreansky M., et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 14 (2004) 676-684
24. Imai C., Iwamoto S., and Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106 (2005) 376-383
25. Finney H.M., Akbar A.N., and Lawson A.D.G. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible co-stimulatory, CD134 and CD137 in series with signals from the TCR-ζ chain. J Immunol 172 (2004) 104-113
26. Geiger T.L., Nguyen P., Leitenberg D., and Flavell R.A. Integrated src kinase and co-stimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 98 (2001) 2364-2371
27. Pule M.A., Straathof K.C., Dotti G., Heslop H.E., Rooney C.M., and Brenner M.K. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12 (2005) 933-941
28. Lenschow D.J., Walunas T.S., and Bluestone J.A. CD28/B7 system of T cell stimulation. Annu Rev Immunol 14 (1996) 233-258
29. Alegre M.L., Faruwirth K.A., and Thompson C.B. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1 (2001) 220-228
30. Hutloff A., Dittrich A.M., Beier K.C., et al. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 397 (1999) 263-266
31. Latza U., Durkop H., Schnittger S., et al. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol 24 (1994) 677-683
32. Alderson M.R., Smith C.A., Tough T.W., et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 24 (1994) 2219-2227
33. + cells. Blood 103 (2004) 3065-3072
34. + T cells and NK cells. J Immunol 175 (2005) 7819-7828
35. Linn Y.C., Lau L.C., and Hui K.M. Generation of cytokine-induced killer cells from leukemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116 (2002) 78-86
36. Ito C., Kumagai M., Manabe A., et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood 93 (1999) 315-320
37. Srivannaboon K., Shanafelt A.B., Todisco E., et al. Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. Blood 97 (2001) 752-758
38. Manabe A., Coustan-Smith E., Behm F.G., Raimondi S.C., and Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 79 (1992) 2370-2377
39. Mihara K., Imai C., Coustan-Smith E., et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 120 (2003) 846-849
40. Darcy P.K., Haynes N.M., Snook M.B., et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 164 (2000) 3705-3712
41. Trinchieri G. The choices of a natural killer. Nat Immunol 4 (2003) 509-510
42. Haynes N.M., Snook M.B., Trapani J.A., Cerruti L., and Smyth M.J. Redirecting mouse CTL against colon carcinoma superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs FCε{lunate}RI-γ. J Immunol 166 (2001) 182-187
43. Eklund J.W., and Kuzel T.M. A review of recent findings involving interleukin-2 based cancer therapy. Curr Opin Oncol 16 (2004) 542-546
44. Grande C., Firvida J.L., Navas V., and Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17 (2006) 1-12
45. Atkins M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12 (2006) 2353s-2358s
46. Wong G.H., Kaspar R.L., Zweiger G., et al. Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin. J Cell Biochem 60 (1996) 56-60
47. Kashii Y., Giorda R., Herberman R.B., Whiteside T.L., and Vujanovic N.L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 163 (1999) 5358-5366
48. Lu G., Janjic B.M., Janjic J., Whiteside T.L., Storkus W.J., and Vujanovic N.L. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 168 (2002) 1831-1839
49. Veldhuis G.J., Willemse P.H., Mulder N.H., Limburg P.C., and De Vries E.G. Potential use of recombinant human interleukin-6 in clinical oncology. Leuk Lymphoma 20 (1996) 373-379
50. Borden E.C., and Chin P. Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 123 (1994) 824-829
51. Baggiolini M., Loetscher P., and Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 17 (1995) 103-108
52. Sebok K., Woodside D., al-Aoukaty A., Ho A.D., Gluck S., and Maghazachi A.A. IL-8 induces the locomotion of human IL-2 activated natural killer cells. Involvement of a guanine nucleotide binding (Go) protein. J Immunol 150 (1993) 1524-1534
53. Masuda Y., Mita S., Sakamoto K., Ishiko T., and Ogawa M. Suppression of in vivo tumor growth by the transfection of the interleukin-5 gene into colon tumor cells. Cancer Immunol Immunother 41 (1995) 325-330
54. Nakashima Y., Mita S., Takatsu K., and Ogawa M. Interleukin-5 induces tumor suppression by peritoneal exudates cells in mice. Cancer Immunol Immunother 37 (1993) 227-232
55. Kataoka S., Konishi Y., Nishio Y., Fujikawa-Adachi K., and Tominaga A. Antitumor activity of eosinophils activated by IL-5 and eotaxin against heaptocellular carcinoma. DNA Cell Biol 23 (2004) 549-560
56. Vicari A.P., and Trinchieri G. Interleukin-10 in viral disease and cancer: exiting the labyrinth?. Immunol Rev 202 (2004) 223-236
57. Mocellin S., Wang E., and Marincola F.M. Cytokines and immune response in the tumor microenvironment. J Immunother 24 (2001) 392-407
58. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 133 (2003) 133-146
59. Ma X., and Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol 79 (2001) 55-92
60. Bellone G., Turletti A., Artusio E., et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155 (1999) 537-547
61. Pollok K.E., Kim Y.-J., Hurtado J., Zhou Z., Kim K.K., and Kwon B.S. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-primed splenic B cells. Eur J Immunol 24 (1994) 367-374
62. + T cell proliferation and lead to amplification in vivo of cytotoxic T cell responses. J Exp Med 186 (1997) 47-55
63. Gramaglia I., Cooper D., Miner K.T., Kwon S., and Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol 30 (2000) 392-402
64. Melero I., Johnston J.V., Shufford W.W., Mittler R.S., and Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190 (1998) 167-172
65. Kim J.A., Averbook B.J., Chambers K., Rothchild K., Kjaergaard J., and Papay R. Divergent effects of 4-1BB antibodies on antitumor immunity abd on tumor-reactive T-cell generation. Cancer Res 61 (2001) 2031-2037
66. Vinay D.S., and Kwon B.S. Immunotherapy targeting 4-1BB and its ligand. Int J Hematol 83 (2006) 23-28
67. Melero I., Shuford W.W., Newby S.A., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 3 (1997) 682-685
68. May K.F., Chen J.L., Zheng P., and Lin Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 62 (2002) 3459-3465
69. Miller R.E., Jones J., Le T., et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 169 (2002) 1792-1800
70. Melero I., Bach N., Hellstrom K.E., Aruffo A., Mittler R.S., and Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 28 (1998) 1116-1121
71. Ito F., Li Q., Shreiner A.B., Okuyama R., Jure-Kunkel M.N., and Teitz-Tennenbaum S. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 64 (2004) 8411-8419
72. Hellstrom K.E., and Hellstrom I. Therapeutic vaccination with tumor cells that engage CD137. J Mol Med 81 (2003) 71-86
73. Kim Y.J., Kim S.H., Mantel P., and Kwon B.S. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell reponses. Eur J Immunol 28 (1998) 881-890
74. Kienzle G., and von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol 12 (2000) 73-82
75. Lucas P.J., Negishi I., Nakayama K., Fields L.E., and Loh D.Y. Naïve CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol 154 (1995) 5757-5768
76. Schweitzer A.N., and Sharpe A.H. The complexity of the B7-CD28/CTLA-4 costimulatory pathway. Agents Actions Suppl 49 (1998) 33-43
77. London C.A., Lodge M.P., and Abbas A.K. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 164 (2000) 265-272
78. Bertram E.M., Lau P., and Watts T.H. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 168 (2002) 3777-3785
79. Diehl L., van Mierlo G.J., den Boer A.T., van der Voort E., Fransen M., and van Bostelen L. In vivo triggering through 4-1BB enables TH-independent priming of CTL in the presence of an intact CD28 costimulatory pathway. J Immunol 168 (2002) 3755-3762
80. Pulle G., Vidric M., and Watts T.H. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 76 (2006) 2739-2748
81. Vinay D.S., and Kwon B.S. Role of 4-1BB in immune response. Semin Immunol 10 (1998) 481-489
82. + killer cells. Ann Hematol 74 (1997) 51-56
83. Ortaldo J.R., Winkler-Pickett R.T., Yagita H., and Young H.A. Comparative studies of CD3- and CD3+CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 136 (1991) 486-495
84. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 68-69